Protara Therapeutics press release (TARA): Q1 GAAP EPS of -$0.31 beats by $0.06. – As of March 31, 2026, unrestricted cash and cash equivalents and marketable debt securities totaled $177.4 million.
The Company expects its cash and cash equivalents and marketable debt securities will be